$1.00B in CY2024 Part D spend219K claims · 32K beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Pimavanserin used for?
NUPLAZID ® is indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis [ see Clinical Studies (14) ] .
Is there a generic for Pimavanserin?
No. Pimavanserin is brand-only with no generic equivalents currently in market.
How much does my plan pay for Pimavanserin?
Across 329 Part D plans, Pimavanserin averages $170.50/unit (NADAC). Lowest available: $170.50/unit. Highest in distribution: $170.50/unit.
Is Pimavanserin on the FDA shortage list?
No. Pimavanserin is not currently on the FDA Drug Shortage Database.
5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (2 approvals on file) · NADAC unit costs: CMS NADAC weekly file (1 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.